[China Pharmaceutical Network Technology News] Experts claim that a breakthrough drug can slow down the condition of Alzheimer's disease, patients taking drugs can significantly delay the rate of mental decline. The world's largest meeting of Alzheimer's disease announced that the drug, called LMTX, can delay the rate of brain atrophy in patients. It is reported that LMTX slows down the rate of brain atrophy in patients with Alzheimer's disease. The drug is dedicated to unravel the tangled proteins that damage nerve cells in the brain and simply solve the symptoms of the disease.
The researchers also said that even some patients can recover their condition. The inventor of the drug, Professor Claude Wischik of the University of Aberdeen, said that this amazing discovery would allow him to apply for a drug patent next year.
If all goes well, his team hopes that the drug will enter the NHS (British National Health Care System) within three or four years. This breakthrough is a major milestone in the history of Alzheimer's disease. However, they are also worried because only 15% of the experimental data in the experimental results can be analyzed. Scholars say that this breakthrough result is very promising, but more research is needed to confirm the effectiveness of LMTX.
At the International Conference of the Alzheimer's Association in Toronto, the study presented hopes that patients could heal, affecting 500,000 people in the UK.
Delaying the condition of Alzheimer's disease allows the patient to live independently and work independently for a longer period of time without relying on others' care. The current Alzheimer's drugs are simple to treat patients with symptoms, but they do not solve the root cause of the disease.
A few international drug companies are now working on drugs that can fundamentally delay the disease. A small company from the University of Aberdeen sells new drugs they develop, which seem to far exceed those of international pharmaceutical giants. This drug is completely different from the treatment used for other drugs. It is the first drug dedicated to solving the problem of protein entanglement in damaged nerve cells, it dissolves a protein called tau and prevents other tangles from forming.
Most companies focus on brain blockage proteins (beta-amyloid), but a series of failures have led experts to question their correctness.
Professor Wischik has led this research since he wrote his doctoral thesis on tau protein 30 years ago and has achieved remarkable results. In the tests of memory and daily task performance, patients who took LMTX had a 85% slower rate of decline than the control group in the past 15 months. The brain scan display showed that they would lose 38% of the brain's material.
Professor Wischik told us: "No previous studies have reached this level. This drug has great clinical efficacy and is very effective in slowing brain atrophy. We have seen that Alzheimer's disease progress has been delayed by 85%, almost minus It’s 15 months slower. Some patients’ brains are developing healthily, and no research has done this before.â€
But others are skeptical about his research. They say that his drug was tested in the latest test, only 135 people. The sample size is too low. Dr. David Reynolds, chief scientific officer of the UK Alzheimer's Disease Research, said: "Obviously, we need more research to understand the mechanism of LMTX and how much benefit LMTX has for Alzheimer's disease."
Dr. Doug Brown, research director of the Alzheimer's Association, said: "This new treatment will have many questions to answer before the future. Why is it taking other drugs to treat Alzheimer's disease? There is no curative effect on people. After years of failure, we have now seen the dawn of hope for Alzheimer's disease trials, and one day the track of Alzheimer's disease will eventually be stopped."
The researchers also said that even some patients can recover their condition. The inventor of the drug, Professor Claude Wischik of the University of Aberdeen, said that this amazing discovery would allow him to apply for a drug patent next year.
If all goes well, his team hopes that the drug will enter the NHS (British National Health Care System) within three or four years. This breakthrough is a major milestone in the history of Alzheimer's disease. However, they are also worried because only 15% of the experimental data in the experimental results can be analyzed. Scholars say that this breakthrough result is very promising, but more research is needed to confirm the effectiveness of LMTX.
At the International Conference of the Alzheimer's Association in Toronto, the study presented hopes that patients could heal, affecting 500,000 people in the UK.
Delaying the condition of Alzheimer's disease allows the patient to live independently and work independently for a longer period of time without relying on others' care. The current Alzheimer's drugs are simple to treat patients with symptoms, but they do not solve the root cause of the disease.
A few international drug companies are now working on drugs that can fundamentally delay the disease. A small company from the University of Aberdeen sells new drugs they develop, which seem to far exceed those of international pharmaceutical giants. This drug is completely different from the treatment used for other drugs. It is the first drug dedicated to solving the problem of protein entanglement in damaged nerve cells, it dissolves a protein called tau and prevents other tangles from forming.
Most companies focus on brain blockage proteins (beta-amyloid), but a series of failures have led experts to question their correctness.
Professor Wischik has led this research since he wrote his doctoral thesis on tau protein 30 years ago and has achieved remarkable results. In the tests of memory and daily task performance, patients who took LMTX had a 85% slower rate of decline than the control group in the past 15 months. The brain scan display showed that they would lose 38% of the brain's material.
Professor Wischik told us: "No previous studies have reached this level. This drug has great clinical efficacy and is very effective in slowing brain atrophy. We have seen that Alzheimer's disease progress has been delayed by 85%, almost minus It’s 15 months slower. Some patients’ brains are developing healthily, and no research has done this before.â€
But others are skeptical about his research. They say that his drug was tested in the latest test, only 135 people. The sample size is too low. Dr. David Reynolds, chief scientific officer of the UK Alzheimer's Disease Research, said: "Obviously, we need more research to understand the mechanism of LMTX and how much benefit LMTX has for Alzheimer's disease."
Dr. Doug Brown, research director of the Alzheimer's Association, said: "This new treatment will have many questions to answer before the future. Why is it taking other drugs to treat Alzheimer's disease? There is no curative effect on people. After years of failure, we have now seen the dawn of hope for Alzheimer's disease trials, and one day the track of Alzheimer's disease will eventually be stopped."
China Extract Powder For Use As Dietary Supplement Extract Powder, Extract Powder Manufacturer
Shaanxi Kang New Pharmaceutical co., Ltd. , https://www.bodybuildingoil.com